[{"address1": "221 Crescent Street", "address2": "Building 23 Suite 105", "city": "Waltham", "state": "MA", "zip": "02453", "country": "United States", "phone": "617 651 5940", "website": "https://www.spyre.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4\u00df7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4\u00df7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4\u00df7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.", "fullTimeEmployees": 30, "companyOfficers": [{"maxAge": 1, "name": "Dr. Cameron  Turtle DPHIL, Ph.D.", "age": 34, "title": "CEO & Director", "yearBorn": 1990, "fiscalYear": 2023, "totalPay": 674168, "exercisedValue": 0, "unexercisedValue": 3315520}, {"maxAge": 1, "name": "Mr. Scott L. Burrows", "age": 47, "title": "Chief Financial Officer", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 331806, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Heidy Abreu King-Jones J.D., L.L.M.", "age": 41, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 568872, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Janet  Gunzner-Toste M.B.A., Ph.D.", "title": "Senior Vice President of Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian  Connolly", "title": "Chief Technical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric  McIntyre", "title": "Vice President of Finance & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James  Myers", "title": "Vice President of Quality & Compliance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kelly  Boothe Ph.D.", "title": "Senior Director of Corporate Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Justin  LaFountaine Ph.D.", "title": "Senior Vice President of Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Melissa  Cooper", "title": "Senior Vice President of People", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 23.28, "open": 23.6, "dayLow": 23.33, "dayHigh": 24.45, "regularMarketPreviousClose": 23.28, "regularMarketOpen": 23.6, "regularMarketDayLow": 23.33, "regularMarketDayHigh": 24.45, "beta": 2.91, "forwardPE": -5.6650834, "volume": 467777, "regularMarketVolume": 467777, "averageVolume": 530130, "averageVolume10days": 511340, "averageDailyVolume10Day": 511340, "bid": 23.69, "ask": 23.98, "bidSize": 100, "askSize": 100, "marketCap": 1426170368, "fiftyTwoWeekLow": 20.07, "fiftyTwoWeekHigh": 47.97, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 29.3043, "twoHundredDayAverage": 30.6717, "currency": "USD", "enterpriseValue": 938911808, "floatShares": 32779174, "sharesOutstanding": 59797500, "sharesShort": 9620365, "sharesShortPriorMonth": 8040536, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.1609, "heldPercentInsiders": 0.08802, "heldPercentInstitutions": 0.88646007, "shortRatio": 14.05, "shortPercentOfFloat": 0.1852, "impliedSharesOutstanding": 59797500, "bookValue": 3.338, "priceToBook": 7.144997, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -214902000, "trailingEps": -37.9, "forwardEps": -4.14, "lastSplitFactor": "1:25", "lastSplitDate": 1694131200, "enterpriseToEbitda": -4.827, "52WeekChange": 0.032830477, "SandP52WeekChange": 0.25443196, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "SYRE", "underlyingSymbol": "SYRE", "shortName": "Spyre Therapeutics, Inc.", "longName": "Spyre Therapeutics, Inc.", "firstTradeDateEpochUtc": 1460035800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "4ccfdc4f-e28e-39a5-bf38-f0def48363db", "messageBoardId": "finmb_253892234", "gmtOffSetMilliseconds": -18000000, "currentPrice": 23.85, "targetHighPrice": 71.0, "targetLowPrice": 40.0, "targetMeanPrice": 58.625, "targetMedianPrice": 65.0, "recommendationKey": "none", "numberOfAnalystOpinions": 8, "totalCash": 414227008, "totalCashPerShare": 8.054, "ebitda": -194508992, "quickRatio": 7.229, "currentRatio": 7.318, "returnOnAssets": -0.38805, "returnOnEquity": -0.91624, "freeCashflow": -60864876, "operatingCashflow": -151247008, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-02"}]